Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 1242 results for public health guidance

  1. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  2. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  3. Ianalumab for treating active Sjogren's syndrome ID6634

    In development Reference number: GID-TA11836 Expected publication date: TBC

  4. Public board meeting agenda and papers May 2025

    Agenda and papers of the NICE public board meeting on 20 May 2025

  5. Learning disability: behaviour that challenges (QS101)

    This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.

  6. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-HTG10171 Expected publication date: TBC

  7. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development Reference number: GID-TA11040 Expected publication date: TBC

  8. Middle meningeal artery embolisation for chronic subdural haematomas

    In development Reference number: GID-HTG10869 Expected publication date:  19 November 2026

  9. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

  10. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

  11. Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]

    Awaiting development Reference number: GID-TA11691 Expected publication date: TBC

  12. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

  13. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date:  13 January 2027

  14. Public board meeting agenda and papers: July 2024

    Agenda and papers of the NICE public board meeting on 17 July 2024

  15. Antimicrobial stewardship (QS121)

    This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.